Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
CNS Drugs August 9, 2023 Meredith Castro, Samuel T. Wilkinson, Rayan K. Al Jurdi et al.
Background: Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 evaluated patients with TRD who received a second induction (IND) and maintenance treatment with ESK...
DOI: 10.1007/s40263-023-01026-3 (opens in new tab)
Full text (opens in new tab)
Ketamine
Humans
Antidepressive agents
Treatment outcome
+5